Condition: Dry Age-related Macular Degeneration · Geographic Atrophy · Sponsor: Regenerative Patch Technologies, LLC
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea. Up to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups: * The treatment group receiving the CPCB-RPE1 implant (up to 18 subjects). * The control group receiving a simulated "sham" implantation procedure (up to 6 subjects)
This description comes directly from the study's public registry record.
Clinical Research · 833-734-3678 · clinicaltrials@regenerativepatch.com
Always discuss trial participation with your own doctor first.
| Retina-Vitreous Associates Medical Group | Beverly Hills, California, United States | Recruiting |
| Retina Associates of Southern California | Huntington Beach, California, United States | Recruiting |
| USC - Keck | Los Angeles, California, United States | Recruiting |
| University Retina | Lemont, Illinois, United States | Recruiting |
| Retina Consultants of Texas | The Woodlands, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06557460